Not exact matches
Indeed, the authors point out that
Ipilimumab might better effect recurrence - free survival than adjuvant interferon and should be considered as an option by oncologists in this field considering its activity across subgroups
including those with high tumor burden.
Dr Larkin said: «Results from our large analysis of pre-defined sub-groups of patients with advanced melanoma provide evidence that suggests the combination of the two drugs consistently improves progression - free survival across a range of sub-groups,
including patients with poor prognostic factors, when compared with either nivolumab or
ipilimumab alone.»
These adverse events resulted in 52 percent of patients on
ipilimumab discontinuing treatment before its completion,
including 39 percent of patients during the first four doses of
ipilimumab.
Checkpoint inhibitors such as
ipilimumab, nivolumab and pembrolizumab have had a dramatic impact on treatment of several tumor types,
including melanoma, lung cancer, head and neck cancers and others.
The study, which
included researchers from 19 countries, compared
ipilimumab treatment in 475 people to placebo treatment in 476 people.
Current clinical trials
include combination of intrahepatic embolization and a radiosensitizer in patients with uveal melanoma and liver - only metastases, a phase I trial that evaluates a combination therapy of BCG with
ipilimumab in Stage III / IV melanoma, and several landmark international trials
including a phase II trial that evaluates combination immunotherapy with nivolumab &
ipilimumab.
The phase III CheckMate 067 trial, which
included 945 untreated melanoma patients, found that nivolumab alone and in combination with
ipilimumab significantly improved progression - free survival (PFS) and the overall response rate (ORR) compared with
ipilimumab alone.
The new drug combination
included Nivolumab, which blocks pD - 1 — a molecule that prevents immune cells recognizing and attacking cancer cells — with
ipilimumab which sensitizes the immune system to cancer cells.